Dendreon Corp. (DNDN)
-NasdaqGS 3.91 
0.04(1.01%) 04:00 SGT|After Hours
:
3.91 0.00 (0.00%) 04:37 SGT
| Prev Close: | 3.95 |
|---|
| Open: | 3.89 |
|---|
| Bid: | 3.87 x 92800 |
|---|
| Ask: | 3.93 x 1000 |
|---|
| 1y Target Est: | 4.98 |
|---|
| Beta: | 2.81 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 3.86 - 3.98 |
|---|
| 52wk Range: | 3.69 - 7.94 |
|---|
| Volume: | 2,226,359 |
|---|
| Avg Vol (3m): | 4,526,490 |
|---|
| Market Cap: | 595.22M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.42 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Commit To Buy Dendreon At $2, Earn 26.5%at TheStreet(Fri, 02:18 SGT)
- Biotech Investing for Beginnersat Motley Fool(Thu, 23 May)
- Dendreon Analysts Getting Very Skepticalat Seeking Alpha(Wed, 22 May)
- Bayer's Xofigo Cleared in the USZacks(Fri, 17 May)
- One Person's Trash Is Another Person's Treasure Portfolioat Motley Fool(Thu, 16 May)
- DENDREON CORP FinancialsEDGAR Online Financials(Thu, 16 May)
- Bayer, Algeta Win U.S. Approval for Prostate Cancer Drugat Bloomberg(Wed, 15 May)
- Today's Market News To Trade On: 5 Stocks Moving On Newsat Seeking Alpha(Wed, 15 May)
- Analysis - A hard day to be a short-seller, one of many this yearat Reuters(Fri, 10 May)
- Dendreon says competition hurt 1Q Provenge salesAP(Fri, 10 May)
- Priority Review for Bayer's DrugZacks(Fri, 15 Feb)
- Encouraging Prelim Results at DNDNZacks(Wed, 9 Jan)
- Dendreon Sells Manufacturing UnitZacks(Fri, 28 Dec)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 1.93 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.55 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.42 |
|---|
| Mean Recommendation*: | 3.4 |
|---|
| PEG Ratio (5 yr expected): | -0.03 |
|---|
Business Summary
Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients.
View More